Pay in 4 interest-free payments of $5.27 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
VIEW AIFA WEBSITE
Please also recommend this newsletter to friends and colleagues - its free
The dispersion between Novo and Lilly again goes to show the incredible power of competition to dictate stock outcomes: despite Novos excellent financial performance since 2023 (31% growth in 2023, 25% growth in 2024, 48% EBIT margins), the stock has declined because of competition: investors think Eli Lilly is the emerging winner within GLP-1s, given the stronger weight loss profile of tirzepatide (Mounjaro/Zepbound) versus semaglutide (Ozempic/Wegovy), and Lillys more attractive weight loss pipeline assets
Early Blood Sugar Control Improvements in blood glucose levels often begin early for those managing type 2 diabetes
This means about 30 new cases have been filed over the last month
US$ 25.31
US$ 21.97
US$ 22.78
US$ 23.01
![Henry Meds Semaglutide Review [2026]](https://innerbody.imgix.net/henry-semaglutide-with-ondansteron-close-up.jpg?auto=format,compress&fit=max&w=826&q=75)
US$ 22.57
US$ 23.01
%25201.png)
![YOKOHAMA BluEarth-GT AE51 205/50R17 93W XL Summer Tires 4 Pieces [h1203342173] Keyence](https://cdn.shopify.com/s/files/1/0712/7370/9816/files/i-img700x700-176000342357980dj5og11201.jpg?v=1765742457)
